Carly Magee is a mother raising two children with hereditary factor X deficiency (Gabe, 20 and Ariel, 18). Both carriers for factor X deficiency, Carly and her husband Brian quickly learned the importance of being advocates for their children’s care. They have also become advocates for others. As such, Carly shares her story about Ariel in hopes that other families can stay informed about factor X deficiency and get connected with the factor X community.
When Carly gave birth to Ariel two years after her son Gabe was diagnosed with hereditary factor X deficiency, the Magees were proactive. Ariel was immediately tested for and diagnosed with hereditary factor X deficiency. While it was “immensely overwhelming” to face the same diagnosis twice, Carly felt empowered to know that Ariel could benefit from the early diagnosis and treatment. For many years, Ariel was treated with Prothrombin Complex Concentrate (PCC).
Through the years, Carly and Brian Magee have stayed informed and connected through social media, their local National Hemophilia Foundation (NHF) chapter, by attending national conferences, and keeping in close contact with their children’s doctor. In fact, it was during a doctor visit in 2015 that Carly first learned about a new development in hereditary factor X deficiency treatment.
With the approval of COAGADEX in 2015, Ariel felt an immediate sense of pride. “It helped her self-esteem and confidence to know that she now has a treatment specifically approved and made for her disease,” Carly said.
Ariel used to wonder if she could manage treatments on her own. Now she feels empowered to self-infuse COAGADEX, and she is attending her college of choice. Carly is proud that Ariel is learning to handle her treatment independently, and she’s inspired by how Ariel manages factor X deficiency with “poise, beauty, and grace.”
Indications for COAGADEX
COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children (aged 12 years and above) with hereditary factor X deficiency for:
- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding in patients with mild hereditary factor X deficiency
Limitation of Use
Perioperative management of bleeding in major surgery in patients with moderate and severe hereditary factor X deficiency has not been studied.
Important Safety Information for COAGADEX
COAGADEX is contraindicated in patients with known hypersensitivity to any of the components of the product.
Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately and contact their physician.
The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.
COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.
In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.
Please see Full Prescribing Information for complete prescribing details.